目的:本研究的目的是评估聚乙二醇400-丙二醇-羟丙基瓜尔胶-透明质酸滴眼液在玻璃体内注射抗VEGF后缓解干眼综合征症状的作用。
方法:在本随机分组中,平行组研究,患者被随机分配接受单独标准治疗或研究滴眼液加标准治疗.入选的患者年龄超过50岁,患有渗出性年龄相关性黄斑变性,从未接受过玻璃体内注射的人,并且没有严重的干眼症或严重的眼部或全身状况。患者进行基线术前评估(V0),连续15天(V1)和30天(V2)后。在VO和V1T-BUT,Schirmer\'stest,荧光素染色,进行DEQ5和OSDI问卷调查,并在V2(30)时进行OSDI问卷调查。
结果:80例患者被纳入研究,其中40人接受了标准治疗加研究滴眼液。DEQ5问卷显示对照组在V0和V1的值之间增加,而在研究组中观察到下降。T-BUT没有变化,Schirmer,两组均观察到V0和V1之间的荧光素染色值。对照组OSDI数据差异无统计学意义,而在研究组中,他们表现出统计学上的显著差异。
结论:在我们的研究中,首次接受玻璃体内治疗的患者在术后期间出现干眼症状:在这组患者中,使用泪液替代品可以减少术后眼部不适。
OBJECTIVE: The purpose of this study is to evaluate the role of a polyethylene glycol 400 - propylene glycol - hydroxypropyl guar - hyaluronic acid eye drops in relieving the symptoms of dry eye syndrome after anti-VEGF intravitreal injection.
METHODS: In this randomized, parallel-group study, patients were randomized to receive standard therapy alone or study eye drops plus standard therapy. Patients enrolled were older than 50 with exudative age-related macular degeneration, who have never had intravitreal injections, and without severe dry eye condition or severe ocular or systemic conditions. Patients had baseline preoperative evaluation (V0), and successively after 15 (V1) and 30 (V2) days. At VO and V1 T-BUT, Schirmer\'s test, fluorescein staining, DEQ5 and OSDI questionnaires were performed and at V2 (30) the OSDI questionnaire was administered.
RESULTS: 80 patients were included in the study, of them 40 received standard therapy plus study eye drops. DEQ5 questionnaire showed an increase in the control group between the values at V0 and V1, while in the study group a decrease was observed. No changes in T-BUT, Schirmer, and fluorescein staining values between V0 and V1 were observed in both groups. OSDI data in the control group showed no statistically significant differences, while in the study group they showed a statistically significant difference.
CONCLUSIONS: In our study patients undergoing for the first time intravitreal treatment presented dry eye symptoms in the postoperative period: in this group of patients the use of a tears substitute reduces postoperative ocular discomfort.